FACIO-SCAPULO-HUMERAL DYSTROPHY
Clinical trials for FACIO-SCAPULO-HUMERAL DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new FACIO-SCAPULO-HUMERAL DYSTROPHY trials appear
Sign up with your email to follow new studies for FACIO-SCAPULO-HUMERAL DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for FSHD: new drug enters final stage of testing
Disease control Recruiting nowThis phase 3 trial tests an experimental drug called AOC 1020 in 200 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. Participants receive either the drug or a placebo by IV infusion. The study measures muscle…
Matched conditions: FACIO-SCAPULO-HUMERAL DYSTROPHY
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for rare muscle disease: experimental drug enters human trials
Disease control Recruiting nowThis study tests an experimental drug called ARO-DUX4 in people with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a genetic condition that causes muscle weakness. The main goal is to check the drug's safety and how the body processes it. About 60 adults and teens will r…
Matched conditions: FACIO-SCAPULO-HUMERAL DYSTROPHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC